Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 2
2001 1
2002 1
2003 1
2004 1
2005 1
2009 2
2010 2
2012 1
2013 1
2015 1
2017 1
2019 1
2020 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

18 results
Results by year
Filters applied: . Clear all
Page 1
Strong vaccine responses during chemotherapy are associated with prolonged cancer survival.
Melief CJM, Welters MJP, Vergote I, Kroep JR, Kenter GG, Ottevanger PB, Tjalma WAA, Denys H, van Poelgeest MIE, Nijman HW, Reyners AKL, Velu T, Goffin F, Lalisang RI, Loof NM, Boekestijn S, Krebber WJ, Hooftman L, Visscher S, Blumenstein BA, Stead RB, Gerritsen W, van der Burg SH. Melief CJM, et al. Among authors: hooftman l. Sci Transl Med. 2020 Mar 18;12(535):eaaz8235. doi: 10.1126/scitranslmed.aaz8235. Sci Transl Med. 2020. PMID: 32188726
Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis.
Barth P, Bruijnzeel P, Wach A, Sellier Kessler O, Hooftman L, Zimmermann J, Naue N, Huber B, Heimbeck I, Kappeler D, Timmer W, Chevalier E. Barth P, et al. Among authors: hooftman l. J Cyst Fibros. 2020 Mar;19(2):299-304. doi: 10.1016/j.jcf.2019.08.020. Epub 2019 Sep 6. J Cyst Fibros. 2020. PMID: 31501052 Free article. Clinical Trial.
Aminopeptidase inhibition as a targeted treatment strategy in myeloma.
Moore HE, Davenport EL, Smith EM, Muralikrishnan S, Dunlop AS, Walker BA, Krige D, Drummond AH, Hooftman L, Morgan GJ, Davies FE. Moore HE, et al. Among authors: hooftman l. Mol Cancer Ther. 2009 Apr;8(4):762-70. doi: 10.1158/1535-7163.MCT-08-0735. Mol Cancer Ther. 2009. PMID: 19372548 Free article.
Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial.
Karpova D, Bräuninger S, Wiercinska E, Krämer A, Stock B, Graff J, Martin H, Wach A, Escot C, Douglas G, Romagnoli B, Chevalier E, Dembowski K, Hooftman L, Bonig H. Karpova D, et al. Among authors: hooftman l. J Transl Med. 2017 Jan 3;15(1):2. doi: 10.1186/s12967-016-1107-2. J Transl Med. 2017. PMID: 28049490 Free PMC article. Clinical Trial.
Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.
Löwenberg B, Morgan G, Ossenkoppele GJ, Burnett AK, Zachée P, Dührsen U, Dierickx D, Müller-Tidow C, Sonneveld P, Krug U, Bone E, Flores N, Richardson AF, Hooftman L, Jenkins C, Zweegman S, Davies F. Löwenberg B, et al. Among authors: hooftman l. J Clin Oncol. 2010 Oct 1;28(28):4333-8. doi: 10.1200/JCO.2009.27.6295. Epub 2010 Aug 23. J Clin Oncol. 2010. PMID: 20733120 Clinical Trial.
A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours.
van Herpen CM, Eskens FA, de Jonge M, Desar I, Hooftman L, Bone EA, Timmer-Bonte JN, Verweij J. van Herpen CM, et al. Among authors: hooftman l. Br J Cancer. 2010 Oct 26;103(9):1362-8. doi: 10.1038/sj.bjc.6605917. Epub 2010 Sep 28. Br J Cancer. 2010. PMID: 20877350 Free PMC article. Clinical Trial.
A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies.
Ossenkoppele GJ, Lowenberg B, Zachee P, Vey N, Breems D, Van de Loosdrecht AA, Davidson AH, Wells G, Needham L, Bawden L, Toal M, Hooftman L, Debnam PM. Ossenkoppele GJ, et al. Among authors: hooftman l. Br J Haematol. 2013 Jul;162(2):191-201. doi: 10.1111/bjh.12359. Epub 2013 May 7. Br J Haematol. 2013. PMID: 23647373 Clinical Trial.
A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.
Banerji U, van Doorn L, Papadatos-Pastos D, Kristeleit R, Debnam P, Tall M, Stewart A, Raynaud F, Garrett MD, Toal M, Hooftman L, De Bono JS, Verweij J, Eskens FA. Banerji U, et al. Among authors: hooftman l. Clin Cancer Res. 2012 May 1;18(9):2687-94. doi: 10.1158/1078-0432.CCR-11-3165. Clin Cancer Res. 2012. PMID: 22553374 Free article.
A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors.
Reid AH, Protheroe A, Attard G, Hayward N, Vidal L, Spicer J, Shaw HM, Bone EA, Carter J, Hooftman L, Harris A, De Bono JS. Reid AH, et al. Among authors: hooftman l. Clin Cancer Res. 2009 Aug 1;15(15):4978-85. doi: 10.1158/1078-0432.CCR-09-0306. Epub 2009 Jul 28. Clin Cancer Res. 2009. PMID: 19638462 Free article. Clinical Trial.
18 results